
Companies pledge to invest over $700 billion in Germany over the next 3 years
The economy has shrunk for the past two years and is expected to stagnate this year. Chancellor Friedrich Merz 's administration has made revitalizing it a top priority since it took office May 6.
It has launched a program to encourage investment and set up a 500 billion euro fund to pour money into Germany's creaking infrastructure over the next 12 years. It is promising to cut red tape and speed up the country's lagging digitization.
On Monday, Merz welcomed representatives of an initiative titled 'Made for Germany' to the chancellery to send a signal of confidence from and to private investors. The group currently includes 61 companies from across the economy, among them industrial conglomerate Siemens and financial giant Deutsche Bank.
'The investments by the initiative are a very powerful signal that we are now experiencing a shift in sentiment and consolidating it," Merz said. 'The message ... is very clear: Germany is back. It's worth investing in Germany again. We are not a location of the past, but a location of the present and above all the future.'
He stressed that private investment is crucial to encouraging growth.
The overall figure pledged Monday includes at least some already planned investments. Merz said the plans include investments in new facilities and in modernizing infrastructure, in research and development.
Deutsche Bank CEO Christian Sewing praised the new government as being 'determined to end the reform backlog that has slowed us down for too long.' But he said that it still needs to do more, and the companies 'encouraged' the government 'to continue the course of reform.'
'Our priorities are clear: We want economic growth, we want to strengthen Germany's competitiveness, we want to defend or further expand our technological leadership and we want to bring our infrastructure into the digital age,' Siemens CEO Roland Busch said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
16 minutes ago
- Reuters
Siemens reduces stake in Siemens Healthineers to 71.12%
MUNICH, July 31 (Reuters) - Siemens AG ( opens new tab reduced its stake in medical technology company Siemens Healthineers ( opens new tab by nearly 2 percentage points to 71.12%, according to a regulatory filing. Healthineers' CEO Bernd Montag said earlier this year that the company would welcome a stake reduction by its parent company, calling it "very good" for the long term. "We have repeatedly and clearly stated that we will reduce our stake in Siemens Healthineers as part of the acquisitions of Altair and Dotmatics, without prejudice to any strategic decisions," a Siemens spokesperson told Reuters on Thursday.


Reuters
16 minutes ago
- Reuters
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
July 31 (Reuters) - AbbVie (ABBV.N), opens new tab raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. Shares of the drugmaker rose nearly 3% to $195.03 before the bell. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023. "We're entering the second half of the year with substantial momentum," said CEO Robert Michael. Skyrizi recorded quarterly sales of $4.42 billion, beating analysts' average estimate of $4 billion, while Rinvoq sales of $2.03 billion surpassed estimates of $1.97 billion, according to data compiled by LSEG. The North Chicago-based drugmaker has spent more than $20 billion on acquisitions since 2023 as Humira lost patent protection. On Wednesday, Bloomberg News reported that AbbVie is in talks to acquire privately held psychiatric disorder drug developer Gilgamesh Pharmaceuticals in a deal worth about $1 billion. Global sales of arthritis treatment Humira, once the world's best-selling drug, came in at $1.18 billion in the second quarter, missing estimates of $1.45 billion. AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the U.S. will be subject to a 15% tariff. AbbVie has a significant manufacturing presence in Ireland, where it makes its wrinkle treatment Botox. The company now expects adjusted annual profit per share between $11.88 and $12.08, compared with its previous expectations of $11.67 to $11.87. The company earned quarterly adjusted profit per share of $2.97, compared with estimates of $2.88.


The Independent
16 minutes ago
- The Independent
999 call handler's voice cloned by AI as part of Russian disinformation campaign
A British 999 call handler's voice was cloned using AI and used as part of a Russian online disinformation campaign. Speaking to the BBC as part of a BBC Verify investigation released on Thursday (31 July), emergency medical advisor Aaron said he was shocked when he found out his voice was being used as part of a campaign designed to spread fear ahead of Poland 's presidential election in May. 'I don't think my friends or family would be able to tell it's fake. I think they probably would have believed it's real.' His voice was taken from a video posted by the North West Ambulance Service which featured Aaron discussing emergency services available during the Easter holidays.